[go: up one dir, main page]

CO6300940A2 - Derivados de espiro-indol para el tratamiento de enfermedades parasitarias - Google Patents

Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Info

Publication number
CO6300940A2
CO6300940A2 CO10148514A CO10148514A CO6300940A2 CO 6300940 A2 CO6300940 A2 CO 6300940A2 CO 10148514 A CO10148514 A CO 10148514A CO 10148514 A CO10148514 A CO 10148514A CO 6300940 A2 CO6300940 A2 CO 6300940A2
Authority
CO
Colombia
Prior art keywords
treatment
plasmodium
espiro
indol
derivatives
Prior art date
Application number
CO10148514A
Other languages
English (en)
Inventor
Shi Hua Ang
Philipp Krastel
Seh Leong
Liying Tan
Wei J Wong
Bryan Yeung
Bin Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300940(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6300940A2 publication Critical patent/CO6300940A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos orgánicos, los cuales tienen propiedades farmacéuticas interesantes. En particular, los compuestos son útiles en el tratamiento y/o la prevención de infecciones tales como aquéllas causadas por Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi y parásitos del género Leishmania, tales como, por ejemplo, Leisbmania donovani. La invención también se refiere a composiciones farmacéuticas que contienen los compuestos, así como a los procesos para su preparación.
CO10148514A 2008-04-29 2010-11-25 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias CO6300940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155342 2008-04-29
EP09151117 2009-01-22

Publications (1)

Publication Number Publication Date
CO6300940A2 true CO6300940A2 (es) 2011-07-21

Family

ID=40613087

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10148514A CO6300940A2 (es) 2008-04-29 2010-11-25 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Country Status (30)

Country Link
US (2) US8053442B2 (es)
EP (2) EP2285808B1 (es)
JP (2) JP5438098B2 (es)
KR (1) KR101390081B1 (es)
CN (1) CN102015711B (es)
AR (1) AR071222A1 (es)
AU (1) AU2009242279B2 (es)
BR (1) BRPI0911577B8 (es)
CA (1) CA2719365C (es)
CL (1) CL2009001007A1 (es)
CO (1) CO6300940A2 (es)
CY (1) CY1114874T1 (es)
DK (1) DK2285808T3 (es)
EA (1) EA019601B1 (es)
EC (2) ECSP10010646A (es)
ES (1) ES2447590T3 (es)
HR (1) HRP20140151T1 (es)
IL (1) IL208357A (es)
JO (1) JO2904B1 (es)
MA (1) MA32316B1 (es)
MX (1) MX2010011868A (es)
MY (2) MY152021A (es)
NZ (1) NZ588217A (es)
PE (1) PE20091787A1 (es)
PL (1) PL2285808T3 (es)
PT (1) PT2285808E (es)
SI (1) SI2285808T1 (es)
TW (1) TWI442921B (es)
WO (1) WO2009132921A1 (es)
ZA (1) ZA201006752B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102015711B (zh) * 2008-04-29 2013-05-01 诺瓦提斯公司 用于治疗寄生虫病的螺-吲哚衍生物
CN102584835B (zh) * 2011-01-17 2014-08-27 苏州大学 一种含吲哚结构的螺杂环化合物及其制备方法
JP6117906B2 (ja) * 2012-03-23 2017-04-19 ノバルティス アーゲー スピロインドロンおよびこれらの中間体を調製するための化学プロセス
DK2828385T3 (en) 2012-03-23 2018-03-12 Codexis Inc BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS
CN104185634B (zh) * 2012-03-23 2017-05-03 诺华股份有限公司 制备螺旋吲哚酮和其中间体的化学工艺
EP3068793B1 (en) 2013-11-13 2021-02-17 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
SG10202012428PA (en) 2014-11-25 2021-01-28 Codexis Inc Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
IL311006A (en) 2014-12-18 2024-04-01 Hoffmann La Roche Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
JP6625649B2 (ja) * 2015-01-23 2019-12-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ピラゾロ［３，４−ｄ］ピリミジン誘導体およびリーシュマニア症の処置のためのその使用
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
US11174267B2 (en) 2015-06-12 2021-11-16 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
JP2017024992A (ja) * 2015-07-15 2017-02-02 公益財団法人微生物化学研究会 化合物の製造方法
IL319761A (en) 2018-06-21 2025-05-01 Hoffmann La Roche Solid forms of 3-((R3,R1)-1-(6,2-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-9,4,3,1-tetrahydro-H2-pyrido[4,3-B]indol-2-yl]2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds containing a substituted phenyl or pyridinyl residue, including methods for using them
CN110590795B (zh) * 2019-10-10 2021-01-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一类多并杂环螺羟吲哚类化合物的合成方法
US20230132973A1 (en) * 2020-03-17 2023-05-04 The University Of Buea DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
CN116273188B (zh) * 2023-03-01 2024-06-25 岭南师范学院 一种负载金属的多孔有机框架材料在催化Pictet-Spengler反应中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NZ509324A (en) * 1998-07-14 2003-07-25 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
SI1144411T1 (en) 1998-12-19 2005-10-31 Janssen Pharmaceutica N.V. Antihistaminic spiro compounds
US20050101623A1 (en) 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
ES2344131T3 (es) 2006-12-07 2010-08-18 F. Hoffmann-La Roche Ag Derivados de espiro-piperidina como antagonistas del receptor v1a.
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5512545B2 (ja) 2008-01-09 2014-06-04 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
CN102015711B (zh) * 2008-04-29 2013-05-01 诺瓦提斯公司 用于治疗寄生虫病的螺-吲哚衍生物

Also Published As

Publication number Publication date
BRPI0911577A8 (pt) 2018-03-06
EP2722333A1 (en) 2014-04-23
CN102015711A (zh) 2011-04-13
ES2447590T3 (es) 2014-03-12
MY152021A (en) 2014-08-15
EA201001689A1 (ru) 2011-08-30
US8399453B2 (en) 2013-03-19
KR101390081B1 (ko) 2014-04-29
BRPI0911577A2 (pt) 2016-01-05
AR071222A1 (es) 2010-06-02
TW200948357A (en) 2009-12-01
CN102015711B (zh) 2013-05-01
CA2719365A1 (en) 2009-11-05
PL2285808T3 (pl) 2014-04-30
MX2010011868A (es) 2010-11-26
WO2009132921A1 (en) 2009-11-05
AU2009242279B2 (en) 2012-08-30
KR20100135320A (ko) 2010-12-24
PT2285808E (pt) 2014-02-24
NZ588217A (en) 2012-10-26
PE20091787A1 (es) 2009-12-14
US20090275560A1 (en) 2009-11-05
HK1149935A1 (en) 2011-10-21
JP5438098B2 (ja) 2014-03-12
MY156601A (en) 2016-03-15
MA32316B1 (fr) 2011-05-02
US20110275613A1 (en) 2011-11-10
BRPI0911577B1 (pt) 2021-02-23
HRP20140151T1 (hr) 2014-03-28
ECSP10010646A (es) 2010-12-30
IL208357A0 (en) 2010-12-30
JO2904B1 (en) 2015-09-15
JP2011518852A (ja) 2011-06-30
EA019601B1 (ru) 2014-04-30
ECSP17068127A (es) 2017-10-31
TWI442921B (zh) 2014-07-01
EP2285808A1 (en) 2011-02-23
CA2719365C (en) 2017-03-07
AU2009242279A1 (en) 2009-11-05
ZA201006752B (en) 2011-05-25
BRPI0911577B8 (pt) 2021-05-25
IL208357A (en) 2014-11-30
US8053442B2 (en) 2011-11-08
EP2285808B1 (en) 2013-11-20
JP2014065729A (ja) 2014-04-17
SI2285808T1 (sl) 2014-03-31
CY1114874T1 (el) 2016-12-14
CL2009001007A1 (es) 2010-06-11
DK2285808T3 (da) 2014-02-03

Similar Documents

Publication Publication Date Title
ECSP17068127A (es) Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
ECSP077894A (es) Antagonistas de npy, preparación y usos
CY1119684T1 (el) Αντι-ιικες ενωσεις
ECSP14017584A (es) Compuestos inhibidores de raf
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
BRPI0916456A2 (pt) composto e composição lipídicos e respectivos métodos de produção e usos (incluindo método de tratamento e de prevenção de doenças que utilizam os mesmos)
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
UY32848A (es) Compuestos heterocíclicos de oxima
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
MX339644B (es) Sales de xantilio 3,6-disustituidas.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
IN2012DN01684A (es)
MX2012003001A (es) Proceso para la produccion de intermediarios de artemisina.
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
PL2515646T3 (pl) Kompozycje zawierające flawonoidy cytrusowe i określone kationowe środki powierzchniowo czynne do leczenia wszawic spowodowanych przez wszy głowowe
TH93138B (th) อนุพันธ์สไปโร-อินโดลสำหรับการบำบัดโรคจากเชื้อปรสิตสาขาวิทยาการที่เกี่ยวข้องกับการประดิษฐ์
TN2010000458A1 (en) Spiro indole derivatives for the treatment of parasitic diseases
TH106774A (th) อนุพันธ์สไปโร-อินโดลสำหรับการบำบัดโรคจากเชื้อปรสิตสาขาวิทยาการที่เกี่ยวข้องกับการประดิษฐ์
UY36469A (es) Nuevo compuesto de tiotriazol

Legal Events

Date Code Title Description
FG Application granted